Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Phase II Study of Envafolimab as First-line Treatment of Aged Patients With High PD-L1 Expression Stage in Advanced Non-small-cell Lung Cancer(NSCLC)

Authors not listed

The First Affiliated Hospital of Xiamen University · 2021

Abstract

Explore the efficacy and safety of Envafolimab in first line treatment of elderly patients with locally advanced or metastatic non-small cell lung cancer with high PD-L1 expression, view to providing better treatment options for elderly patients with high PD-L1 expression and improving the survival and prognosis of patients .

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-04 MST

Cite this

APA
Anonymous. (2021). A Phase II Study of Envafolimab as First-line Treatment of Aged Patients With High PD-L1 Expression Stage in Advanced Non-small-cell Lung Cancer(NSCLC). <em>The First Affiliated Hospital of Xiamen University</em>. https://clinicaltrials.gov/study/NCT05055167
Vancouver
Anonymous. A Phase II Study of Envafolimab as First-line Treatment of Aged Patients With High PD-L1 Expression Stage in Advanced Non-small-cell Lung Cancer(NSCLC). The First Affiliated Hospital of Xiamen University. 2021.
BibTeX
@misc{anon2021APhase, title = {A Phase II Study of Envafolimab as First-line Treatment of Aged Patients With High PD-L1 Expression Stage in Advanced Non-small-cell Lung Cancer(NSCLC)}, author = {Anonymous}, journal = {The First Affiliated Hospital of Xiamen University}, year = {2021}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings